The novel myostatin-specific sweeping antibody GYM329 and its surrogates significantly enhanced muscle strength and increased muscle mass in mouse models of muscle disease and cynomolgus monkeys.
Does GYM329 improve muscle strength and mass in preclinical models of muscle disease?
A novel latent myostatin-specific sweeping antibody, GYM329, provides superior muscle strength enhancement in preclinical models compared to conventional anti-myostatin agents.
Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeutic approach that maximizes the potential of myostatin-targeted therapy. We generated an antibody, GYM329, that specifically binds the latent form of myostatin and inhibits its activation. Additionally, via "sweeping antibody technology", GYM329 reduces or "sweeps" myostatin in the muscle and plasma. Compared with conventional anti-myostatin agents, GYM329 and its surrogate antibody exhibit superior muscle strength-improvement effects in three different mouse disease models. We also demonstrate that the superior efficacy of GYM329 is due to its myostatin specificity and sweeping capability. Furthermore, we show that a GYM329 surrogate increases muscle mass in normal cynomolgus monkeys without any obvious toxicity. Our findings indicate the potential of GYM329 to improve muscle strength in patients with muscular disorders.
Muramatsu et al. (Mon,) conducted a other in Muscle disease models (DMD, muscular atrophy, sarcopenia). GYM329 (and surrogates GYM-mFc, GYM-cyFc) vs. Vehicle and conventional anti-myostatin agents (landogrozumab, domagrozumab, bimagrumab) was evaluated on Muscle strength and muscle mass. The novel myostatin-specific sweeping antibody GYM329 and its surrogates significantly enhanced muscle strength and increased muscle mass in mouse models of muscle disease and cynomolgus monkeys.